Literature DB >> 15957833

[Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy].

Hai-xiang Song1, Jing Gong, Wen Chen.   

Abstract

OBJECTIVE: To observe the change of urinary monocyte chemottractant protein-1 (MCP-1) in patients with diabetic nephropathy (DN), and to explore the therapeutic effect and mechanism of triptolide (TL) in treating DN.
METHODS: Thirty-five patients in the treated group were treated with TL plus benazepril and thirty two patients in the control group were treated with benazepril alone for six months. The change of urinary MCP-1 was measured before and after treatment.
RESULTS: Level of urinary MCP-1 in DN patients was significantly higher than that in healthy subjects (P < 0.01), but it could be significantly decreased after TL treatment, showing significant difference as compared with that in the control group (P < 0.05).
CONCLUSION: Determination of urinary MCP-1 level is beneficial to know the degree of kidney inflammation in DN patients. TL can inhibit inflammatory reaction to decrease the level of urinary MCP-1, and thus improve the renal function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957833

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  13 in total

Review 1.  Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae).

Authors:  Anita M Brinker; Jun Ma; Peter E Lipsky; Ilya Raskin
Journal:  Phytochemistry       Date:  2007-01-23       Impact factor: 4.072

2.  Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102.

Authors:  John M Fidler; Jinhua An; Bing Z Carter; Michael Andreeff
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-12       Impact factor: 3.333

Review 3.  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Authors:  Jun Panee
Journal:  Cytokine       Date:  2012-07-04       Impact factor: 3.861

Review 4.  Immunoregulatory effects of Tripterygium wilfordii Hook F and its extracts in clinical practice.

Authors:  Dan Luo; Zhengyun Zuo; Hongyan Zhao; Yong Tan; Cheng Xiao
Journal:  Front Med       Date:  2019-01-02       Impact factor: 4.592

5.  Impairment of triptolide on liver mitochondria in isolated liver mitochondria and HL7702 cell line.

Authors:  Qiang Fu; Zhen-zhou Jiang; Lu-yong Zhang
Journal:  Chin J Integr Med       Date:  2013-04-10       Impact factor: 1.978

6.  Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease.

Authors:  Ruixia Ma; Yan Xu; Wei Jiang; Wei Zhang
Journal:  Biotechnol Biotechnol Equip       Date:  2014-12-11       Impact factor: 1.632

7.  Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis.

Authors:  Yan Hong; Zhihong Gui; Xiaoping Cai; Lejian Lan
Journal:  Open Med (Wars)       Date:  2016-12-30

Review 8.  Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy.

Authors:  Guang-dong Sun; Chao-yuan Li; Wen-peng Cui; Qiao-yan Guo; Chang-qing Dong; Hong-bin Zou; Shu-jun Liu; Wen-peng Dong; Li-ning Miao
Journal:  J Diabetes Res       Date:  2015-11-15       Impact factor: 4.011

9.  Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy.

Authors:  Ruixia Ma; Liqiu Liu; Xuemei Liu; Yan Wang; Wei Jiang; Luo Xu
Journal:  Exp Ther Med       Date:  2013-07-17       Impact factor: 2.447

Review 10.  Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review.

Authors:  Samira Ziaei; Reginald Halaby
Journal:  Avicenna J Phytomed       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.